Sorafenib

Abstract

Sorafenib Hand-foot skin reaction in an elderly patient: case reportA 76-year-old man developed a hand-foot skin reaction while receiving sorafenib. The man had a history of hepatocellular carcinoma (HCC), chronic hepatitis C virus infection and gastric cancer. He started receiving sorafenib 800 mg/day for lung metastatic tumours [route not stated]. He experienced a hand-foot skin reaction [time to reaction onset not stated]. His sorafenib dose was reduced to 200 mg/day. He was subsequently diagnosed with intracranial metastasis of gastric cancer. Following successful tumour removal, sorafenib was discontinued [ADR outcome not stated]. Author comment: "Subsequently, sorafenib was administered. Because of adverse events such as a hand-foot skin reaction, the dose of sorafenib was reduced from 800 to 200 mg/day." Tawada A, et al. Intracranial metastasis in a patient with hepatocellular carcinoma and gastric cancer.